NasdaqGS - Nasdaq Real Time Price USD

Intra-Cellular Therapies, Inc. (ITCI)

73.12

-0.89

(-1.20%)

At close: April 24 at 4:00 PM EDT

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has completed the sale of an additional 1,027,397 shares of its common stock at a public offering price of $73.00 per share on April 24, 2024, pursuant to the full exercise of the option granted by Intra-Cellular Thera

GlobeNewswire 13 hours ago
Intra-Cellular Therapies Prices Public Offering of Common Stock

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share. All of the shares in the offering will be sold by Intra-Cellular Ther

GlobeNewswire 7 days ago
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to

GlobeNewswire 8 days ago
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.9 point reduction v. placebo; p<0.0001; Cohen’s d effect size (ES)= 0.61) Lumateperone 42 mg also met the key secondary endpoint of change from baseline at Week 6 on the Clinical Global Impressio

GlobeNewswire 8 days ago
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company

GlobeNewswire last month
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences: Leerink Partners Global Biopharma ConferenceTuesday, March 12, 2024 at 10:40 a.m. ET in Miami, FL Jefferies Biotech on the Bay Summit Wednesday, March 13, 2024 in Miami, FL UBS Virtual CNS D

GlobeNewswire last month
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA. The live and archived webcast can be accessed under "Events

GlobeNewswire last month
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update

Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million, representing year-over-year growth of 86%. CAPLYTA fourth quarter 2023 net product sales grew to $131.5 million, a 50% increase over the same period in 2022 In 2023, CAPLYTA total prescriptions achieved strong year-over-year growth of 85% CAPLYTA 2024 net product sales guidance of $645 to $675 million NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Intra-C

GlobeNewswire 2 months ago
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 22, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2023. To a

GlobeNewswire 2 months ago
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA. The live and archived webcast can be accessed und

GlobeNewswire 3 months ago
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting

Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients experiencing a major depressive episode with anxious distress and mixed features. Company presents preclinical data on ITI-1549, our lead product candidate in our non-hallucinogenic psychedelics program in mood disorders and other psychiatric disorders. NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biophar

GlobeNewswire 4 months ago
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 3:25 p.m. ET in Miami, FL. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Comp

GlobeNewswire 5 months ago
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 CAPLYTA Q3 2023 net product sales were $125.8 million, compared to $71.9 million for the same period in 2022, representing a 75% increase CAPLYTA’s strong prescription uptake continues: Q3 2023 CAPLYTA total prescriptions increased 71%, versus the same period in 2022 2023 CAPLYTA net product sales guidance raised to $460 - $470 million NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellula

GlobeNewswire 5 months ago
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences: J.P. Morgan Equity Opportunities ForumMonday, November 6 – Tuesday, November 7, 2023 in Miami, FL UBS Biopharma Conference 2023Wednesday, November 8, 2023 at 11:00 a.m. ET. in Miami, FL A live

GlobeNewswire 5 months ago
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 2, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2023. To attend the

GlobeNewswire 5 months ago
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:15 p.m. ET. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company

GlobeNewswire 7 months ago
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 12:55 p.m. ET. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Comp

GlobeNewswire 7 months ago
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:30 p.m. ET. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's websit

GlobeNewswire 8 months ago
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022 CAPLYTA Q2 2023 net product sales were $110.1 million, compared to $55.1 million for the same period in 2022, representing a 100% increase CAPLYTA’s strong prescription uptake continues: Q2 2023 CAPLYTA total prescriptions increased 96%, versus the same period in 2022 and 13% sequentially versus Q1 2023 2023 CAPLYTA net product sales guidance raised to $445 - $465 million NEW YORK, Aug. 03, 2

GlobeNewswire 8 months ago
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 3, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2023. To attend the live c

GlobeNewswire 8 months ago

Performance Overview

Return	ITCI	S&P 500
YTD	+2.09%	+6.33%
1-Year	+16.97%	+22.70%
3-Year	+135.42%	+21.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Intra-Cellular Therapies Prices Public Offering of Common Stock

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast

Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting

Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference

Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast

Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

Performance Overview